Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia and various AF disease management strategies can be utilized.
Methods: A prospective, randomized pilot study of two AF disease management strategies was conducted at a single university hospital in patients newly diagnosed with AF. The impact of low molecular weight heparin (LMWH) on AF management strategies is discussed with respect to the current guidelines for AF management, existing data on LMWH for AF, and recent investigations pertaining to AF.
Results: 18 patients were enrolled. The accelerated emergency department based strategy utilizing LMWH resulted in a significant reduction in length of stay (2.1 ± 2.3 versus <1 day) and a trend toward lower costs ($1,706 ± 1,512 versus $879 ± 394; p = 0.15) when compared to the more traditional strategy of hospital admission. Measured clinical outcomes were similar for both treatment strategies.
Conclusions: The investigation showed that an outpatient, emergency department based disease management strategy for new, uncomplicated AF could result in clinically acceptable, cost-effective innovations in AF treatment strategies. LMWH is an example of an agent allowing innovations in disease management strategies.
- Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of undiagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–2375.
- Kim MH, Morady F, Conlon B, Kronick S, Lowell M, Bruckman D, Armstrong WF, Eagle KA. A prospective, randomized, controlled trial of an emergency departmentbased atrial fibrillation treatment strategy with lowmolecular-weight-heparin. Ann Emerg Med 2002;40:187–192.
- ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. JAmColl Cardiol 2001;38:1–35.
- Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692–1711.
- Connolly SJ. Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. Am Heart J 2003;145:418–423.
- Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: Summary of the literature. Am J Health-Syst Pharm 2002;59(Suppl 6):S7–14.
- Kim MH, Decena BF, BruckmanD, Eagle KA. Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. Am Heart J 2003;145:665–669.
- The Advisory Board Company (Cardiovascular Roundtable). Post-CABG atrial fibrillation: Advanced strategies for prevention and efficient treatment. Washington, D.C., 2000.
- Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, Schlierf G. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemostas 1993;19 (Suppl 1):116–121.
- Harenberg J, HuhleG, Piazolo L, Giese C, Heene DL. Longterm anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular weight heparin. Semin Thromb Hemostas 1997;23:167–172.
- Roijer A, Eskilsson J, Olsson B. Transesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Eur Heart J 2000;21:837–847.
- Philippon F, O'Hara GE, Champagne J, Charbonneau L, Villeneuve H, Blier L, Molin F, Gilbert M. DALTON Study: A randomized study comparing outpatient dalteparin administration to inpatient heparin for the initiation of anticoagulation in atrial fibrillation. JAmColl Cardiol 2003;41 (Suppl A):85A (abstract).
- Nixdorff U, Stellbrink C, Hofmann T, Hanrath P, Lehmacher W, Schmidt-Lucke A, for the ACE Investigators. Comparison of the safety and efficacy of enoxaparin with unfractionated heparin and phenprocoumon as anticoagulation in cardioversion of nonvalvular atrial fibrillation. J AmColl Cardiol 2003: 41(Suppl A):85A (abstract).
- Albers GW, Dalen JE, Laupacis A, Manning WJ, Peterson P, Singer DE. Antithrombotic therapy in atrial fibrillation (Sixth ACCP Consensus Conference on Antithrombotic Therapy). Chest 2001;119 (Suppl):194S–206S.
- Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. AmJ Cardiol 1969;23:208–216.
- Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or flutter. J AmColl Cardiol 1992;19:851–855.
- Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411–1420.
- Murray RD, Deitcher SR, Shah A, Jasper SE, Bashir M, Grimm RA, Klein AL. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided lowmolecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 2001;14:200–208.
- Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz WE, Malouf JF, Stoddard MF, Grimm RA, Klein AL, for the ACUTE II pilot study. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: The ACUTE II pilot study. Am Heart J 2000;139:e5.
- Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kuhle K, Fetsch T, Grewe R, Schmidt-Lucke JA. Anticoagulation in cardioversion using enoxaparin study group. Zeitschrift fur Kardiologie 2002;91:249–254.
- The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.
- Lip GYH, Hart RG, Conway DSG. Antithrombotic therapy for atrial fibrillation. BMJ 2002;325:1022–1025.
- Sherman DG, Kim S, Boop B, Corley S, DiMarco J, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim M, Nasco E, Waldo A, for the AFFIRM Investigators. The occurrence and characteristics of stroke events in the AFFIRM study. Neurology 2003;60(Suppl 1):A326 (abstract).
- Zimetbaum PJ, Josephson ME, McDonald MJ, McClennen S, Korley V, Ho KK, Papageorgiou P, Cohen DJ. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 2000;36:1223–1227.
- Koenig BO, Ross MA, Jackson RE. An emergency department observation unit protocol for acute-onset atrial fibrillation is feasible. Ann Emerg Med 2002;39:374–381.
- Mulcahy B, Coates WC, Henneman PL, Lewis RJ. New-onset atrial fibrillation: When is admission medically justified? Acad Emerg Med 1996;3:114–119.
- Weigner MJ, Thomas LR, Patel U, Schwartz JG, Burger A, Douglas PS, Silverman DI, Manning WJ. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: Short-term safety and impact on maintenance of sinus rhythm at one year. Am J Med 2001;110:694–702.
- Kim MH, Krishnan K, Jain S, Decena BF. Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter. Am J Cardiol 2001;88:1428–1431.
- Ginsberg JA, Crowther MA, White RH, Ortel TL. Anticoagulation therapy. Hematology 2001:339–357.
- Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
Cardiac Electrophysiology Review
Volume 7, Issue 4 , pp 397-400
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- low molecular weight heparin
- atrial fibrillation